BioSupply Trends Quarterly logo
Subscribe

Biosimilars Debut in the U.S.

In light of the angst and hand-wringing over the soaring costs of biologic drugs that are alleged to be contributing to the unsustainability of biologic treatments, the U.S. Food and Drug Administration (FDA) approval of the first biosimilar in the U.S. was welcome news to many.

Payments for Healthcare: A New Day Is Coming

In late January, the Department of Health and Human Services (HHS) announced that it would fundamentally reform how it pays providers for treatingMedicare patients in the coming years. Speeding up the transition from fee-for-service to pay-for-performance and forcing Medicare to commit to this payment

OPPS 2015 Final Rule: Impact from a Pharmaceutical Perspective

On Oct. 31, the Centers for Medicare and Medicaid Services (CMS) issued the calendar year 2015 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory SurgicalCenter Payment System Policy Changes and Payment Rates final rule [CMS-1613-FC].

Immune Globulin: Controlling Supply and Demand

BioSupply Trends Quarterly Winter 2015 MImmune Globulin

While the healthcare industry is currently experiencing an oversupply of the lifesaving immune globulin therapy, with demand growing at 6 percent to 8 percent a year, is it possible another shortage looms large?

The Age of Telemedicine

Medicine has come into the electronic age with telemedicine, which provides wider reaching care in an era when there is a projected doctor shortage.

Specialty Pharmacies and Delivery Models

Today’s evolving healthcare delivery models increasingly require organized, careful multidisciplinary approach that supports the use of specialty medications.